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44% CV death 

Prevalence of hypertension in solid organ transplantation 
Adapted from Glatz N. 
Organ At 1 year At 5 years 
Kidney ~ 80% ~ 95% 
Liver ~60-70% ~ 60% 
Heart ~ 70% ~ 95% 
Lungs ~ 50% ~ 80% 
Office Blood Pressure and kidney graft failure risk  
in transplanted patients  
Opelz et al. Am J Transplant 2005; 5: 2725  
20% difference 
in graft survival 
Prevalence of different forms of hypertension: 
true, white coat or masked HTA 
N=98 Kidney Tx 
HT office >130/80 mmHg 
HT ABPM definition: 
-Day     >130/80 mmHg 
-24h >125/75 mmHg 
-Night >120/70 mmHg 
 
 
42% have their antiHTA  
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Baseline visit (N=70), personal data 
Blood Pressure control in treated hypertensive  Ktr  
according to office and out-of-clinic BP measurements 
  















Post-transplant HTA:potential mechanisms 
Immune 
Optimal BP target? 
• HT in KT is prevalent, multifactorial and 
associated with a bad prognosis. 
• However, no RCT have been realized to examine 
optimal levels of BP in KTR to prolong graft 
survival or limit the risk of CV events 
 KDIGO 
KDIGO 2012: <130/80 mmHg 
ESH 2013 or JNC8 2014: No recommendation for the BP target in KTR! 
SBP: impact on CV events and death 
DBP: impact on CV events and death 
Treatment approach to hypertension 
• Therapeutic lifestyle changes1 
• Antihypertensive agents1 
• Alter immunosuppressive regimen2 
 
 1K/DOQI clinical practice guidelines on hypertension and antihypertensive  
agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1-290 
²Fellström B. BioDrugs 2001;15:261-78 
Therapeutic lifestyle changes (similar to ESH 2013) 
• Salt restriction (<100 mmol/d) 
• Moderation of alcohol intake  
• Regular exercise (5-7 d/ w) 
• Reduction of weight if BMI > 
25 Kg/m²  
Treatment approach to KT hypertension 
 
• Therapeutic lifestyle changes 









Saint-Remy A et al BMC Nephrology 2012; 13: 121 
Influence of IS modification 
• Steroids cessation:  
- small decrease in BP prevalence (-10%), higher effect on 
hypercholesterolemia (-24%) and on DM risk(-36%) 
(Pasqual et al T 2006, Woodle et al Ann Surg 2008) 
- small risk of Acute Rejection without significant effect on 
long term graft function.  
• CNI: 
-  Lowering BP by either reducing CNI dose, converting 
Cyclosporine to Tacrolimus or by substituting it (after 3m). 
Treatment approach to KT hypertension 
• Drug treatment: each class is possible according 
to the patient, but most patients require more 
than one agent to achieve BP control targets 
 
Potential advantage but also risk of antiHT drugs in 
KTR 
• Diuretics attenuate saline retention but can create 
    functional AKI, hypoK and Mg, sexual trouble  
• BBlockers decrease morbidity and mortality after MI and 
in CHF (KTR have high CV risk) but can generate 
• sexual dysfunction, dyslipidemia, DM risk 
• Non DHP CCB: increase in CNI blood concentration, So 
can spare drug use but if not adapted caused 
nephrotoxicity 
• DHP CCB attenuate the nephrotoxicity of CNI but can 
create gum hypertrophy 
Inhibitors of RAS (RASI) 
ACEI or AIIRA could be useful in proteinuric 
patients, in post-transplant erythrosis or when LVH 
But there is a controversial interest  for their use for 
graft survival ! 

Antihypertensives for kidney transplant recipients 
N Cross et al  Transplantation July 2009 
RAS Blockers or DHP CCB:  
• - Lower GFR with RAS Blockers 
• - reduction of proteinuria and hemoglobin 
• - small increase in kalemia 
• -  not higher risk for graft loss! 
 
• Interest of RAS Blockers in proteinuric patients 
(CAN)? 
Some trials comparing RASI and 
other Treatment in KT with HT  
Some more recent randomized trials: 
•1. SECRET study (3y)(Philipp et al NDT 2010):       
no significant benefit on kidney function by 
candesartan but it is safe with higher effect on 
lowering of BP and proteinuria 
•2. Ibrahim et al (JASN 2013) (5y): no statistical 
significant benefit with losartan on IF/TA, but well 
tolerated and can reduce the doubling serum 
creatinine rate. 
 
3. Ramipril versus placebo in kidney transplant patients 
with proteinuria: a multicenter, double-blind, randomized 
controlled trial (G Knoll et al Lancet diabetes-endocrine 2015) 
• Study in Canada and New Zealand, adult renal TR at least 3-months 
post-transplant with an eGFR of 20 mL/min/1·73m2 or greater and 
proteinuria 0·2 g per day or greater. 
• They were randomly assigned to receive either Ramipril (5 mg orally 
twice daily) or placebo for up to 4 years, with an extended period of 4y. 
Pl         R 
 Lower BP in the ramipril 
group (-5/-3 mmHg) 
Inhibitors of RAS (RASI) 
• However, RASI should be avoided in the early 
post-transplantation period due to hemodynamic 
effect on GFR and K homeostasis and in any 
situation characterized by hemodynamic 
instability. 
How to manage HT according to the KTr period? 
• During the 1st month after KTr: role of volume overload, high dose 
of CST and CNI, DGF, technical problem (Kinking transplant renal 
artery, Page Kidney).  
   Best antiHT choice : CCB, Bblocker and sometimes diuretics. 
   Target BP : 140-150 mmHg 
 
• Between the 1st and the 4th month after KTr:  
    Target SBP <140 mmHg,  
     Look for 2ary HT (TRAS and other classic forms of HT) 
 
• After the 4th month of KTr: look for all CV risk factors, target SBP 
<130 mmHg if possible 
How to manage HT according to the KTr period? 
If uncontrolled HT,  
• check for drug compliance and true HT by out-of-the clinic BP 
measurements,  
• check for salt, potassium intakes and weight change,  
• try to modify IS therapy,  
• look for secondary HT (SAS, TRAS, endocrine disorders,..) 
• introduce spironolactone if kalemia is correct 
• discuss for bilateral native nephrectomy if remaining resistant HT. 
MR angiography 
Renal artery stenosis 
Transplant RAS 
• 1-25% of KTR 
• RF: CMV infection, DGF, surgical techniques, humoral rejection 
• Clinical presentation similar to native Kidney RAS 
• Diagnosis: Colour doppler sonography (sometimes MRI angiography) 
• Conventional angiography (gold standard confirmation test) 
• Biopsy of the graft could be useful before angioplasty (CAN) 
• Treatment: possible spontaneous regression !,  
     Angioplasty (with or without stent placement): (J Transplantation 2011) 
     - high technical success (88-100%),  
     - lower clinical success (67-90%)  
     - some complications of the procedure (3-25%) 
Hypertension in KTr: Conclusions 
• Hypertension is frequent , often multifactorial and a risk factor for 
development of CVD and poor graft function. 
• A global strategy is needed to manage high BP and the CV risk, 
improving the accuracy of BP measurements. 
• Similar management is proposed as in the general population, but 
with a suggested BP target <130/80 mmHg. 
• Further improvement in BP control could be achieved by tapering or 
discontinuation of steroids and/or CNI (especially cyclosporine). 
• The first line antihypertensive therapy seems CCBl and/or BBlocker. 
• Don’t forget poor compliance and secondary HTA if resistance ! 
Thank you for your attention 
Questions? 
